- Combined immunotherapy shows promising success Neck and head cancers
- Treatment with Ipilimumab and nivolumab
- British Cancer patient told of Treatment success
- Further Studies planned
At least Barry Ambrose from Bury St Edmunds (Great Britain) was able to save the new immunotherapy: The 77-year-old, who was diagnosed with throat cancer in 2017, took one in England Drug study part in which the two Active ingredients ipilimumab and nivolumab combined used to treat patients with neck or head tumors. “What did I have to lose,” said Ambrose to the London resident “Institute of Cancer Research” (ICR), which presented the results of the study.
Increased life expectancy, more quality of life
Accordingly, the new immunotherapy would have the Life expectancy of cancer patients with neck or head cancer significantly extended – while at the same time fewer side effects occurred than with standard chemotherapy treatment. “Despite the lack of significance, the results are clinically significant,” said Professor Kevin Harrington, who was involved in the study, optimistically. However, more research is needed.
Barry Ambrose calls the treatment at least a “lifeline”. Even if the therapy was less effective for his lung cancer, which had also occurred, Ambrose was able to take a cruise to the Caribbean with his wife in the meantime. After all, it was his Larynx cancer completely gone. “It was a fantastic moment when the nurses called me and told me that the tumor in my throat was completely gone,” recalls Ambrose.
The two active ingredients ipilimumab and nivolumab should, according to the report Stimulate the immune system to attack and kill the cancer cells. Some successes have already been achieved with the combination of both drugs.
Im November 2020 was the combination of both active ingredients in Germany Approved as a treatment for metastatic lung cancer. The tumor is first surgically removed and the treatment is supported by chemotherapy. According to studies, the treatment would also have had a positive effect on the life expectancy of the patients. According to Spiegel, the treatment had also proven itself in skin cancer, kidney cancer or colon cancer.